Acerta Pharma
CompanyNetherlands
Acerta Pharma develops one asset, in phase 2 (acalabrutinib in rheumatoid arthritis). Mostly small molecule acting on inflammation and BTK; based in Netherlands.
- 1
- Asset
- Furthest stage
- Phase 2
- 6
- Trials
- 1
- Signal
Pipeline
1Inhibits Bruton tyrosine kinase, reducing B-cell receptor signaling and inflammatory immune activation.
Phase 2, Small molecule, Inflammation, BTK, rheumatoid arthritis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials8
- Signals1
- Integrity notices1
- Similar companies6